GlaxoSmithKline plc (LON:GSK) insider Simon Dingemans bought 7 shares of the company’s stock in a transaction that occurred on Tuesday, October 11th. The stock was bought at an average price of GBX 1,728 ($21.39) per share, with a total value of £120.96 ($149.70).

GlaxoSmithKline plc (LON:GSK) traded down 1.11% on Wednesday, reaching GBX 1700.00. 6,394,002 shares of the company traded hands. The company has a 50-day moving average price of GBX 1,647.81 and a 200-day moving average price of GBX 1,559.14. GlaxoSmithKline plc has a 12 month low of GBX 1,277.25 and a 12 month high of GBX 1,745.56. The company’s market capitalization is GBX 82.64 billion.

Insider Buying and Selling by Quarter for GlaxoSmithKline plc (LON:GSK)

The business also recently disclosed a dividend, which will be paid on Thursday, October 13th. Shareholders of record on Thursday, August 11th will be issued a dividend of GBX 19 ($0.24) per share. This represents a yield of 1.12%. The ex-dividend date is Thursday, August 11th.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

Several analysts recently weighed in on the stock. Credit Suisse Group AG reiterated a “neutral” rating and issued a GBX 1,800 ($22.28) target price on shares of GlaxoSmithKline plc in a report on Thursday, July 14th. S&P Global Inc. set a GBX 1,650 ($20.42) target price on shares of GlaxoSmithKline plc and gave the company a “neutral” rating in a report on Wednesday, July 27th. Beaufort Securities reiterated a “buy” rating on shares of GlaxoSmithKline plc in a report on Tuesday, June 21st. BNP Paribas restated a “neutral” rating on shares of GlaxoSmithKline plc in a research note on Friday, July 29th. Finally, Citigroup Inc. set a GBX 1,800 ($22.28) price target on shares of GlaxoSmithKline plc and gave the stock a “buy” rating in a research note on Thursday, September 29th. Three research analysts have rated the stock with a sell rating, fifteen have issued a hold rating and eight have assigned a buy rating to the company’s stock. GlaxoSmithKline plc currently has an average rating of “Hold” and an average price target of GBX 1,685.04 ($20.85).

About GlaxoSmithKline plc

GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.

Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with's FREE daily email newsletter.